Dehydrogenases

Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive drug.

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

DSM265 is a long-duration, potent and selective dihydroorotate dehydrogenase (DHODH)) inhibitor.

PTC299 is a potent, orally bioavailable VEGFA inhibitor, targets dihydroorotate dehydrogenase (DHODH), resulting in cell growth inhibition and differentiation in leukemias, including acute myeloid leukemia, linking DHODH regulation and stress-induced VEGFA and angiogenesis.

RV01 is an analogue of resveratrol, inhibits DNA damage, reduces acetaldehyde dehydrogenase 2 (ALDH2) mRNA expression induced by ethanol, and exhibits hydroxyl radical scavenging activity. RV01 decreases iNOS expression, with anti-neuroinflammatory activity.

Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.